Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Zijin Mining Shares Hit Record High on $4 Billion Allied Gold Acquisition 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
Boeing Posts Fourth-Quarter Profit on Jeppesen Sale Despite Ongoing Unit Losses 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
NEW YORK, May 18, 2017 -- Cortice Biosciences announced today that final results from the dose-escalation portion of a Phase 1/2 clinical trial evaluating TPI 287 for treatment of recurrent glioblastoma (GBM) will be presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, IL. These results will be presented during the Central Nervous System Tumors Poster Session on Monday, June 5, and reviewed during a poster discussion session later that afternoon.
Title: Final results from the dose-escalation stage of a Phase 1/2 trial of TPI 287, a brain penetrable microtubule inhibitor, plus bevacizumab in patients with recurrent glioblastoma
Date: Monday, June 5
Display time: 1:15 – 4:45 PM CDT
Discussion: 4:45 – 6:00 PM CDT
Abstract #: 2021
Presenter: Samuel Goldlust, M.D., John Theurer Cancer Center, Hackensack, NJ
About TPI 287
TPI 287 is a novel taxoid which binds to and stabilizes the assembly of microtubules similarly to commonly used taxanes, including paclitaxel (Taxol® and Abraxane®) and docetaxel (Taxotere®). In oncology treatment settings, microtubule stabilization by these agents leads to mitotic arrest and cancer cell death. TPI 287 has advantages over these taxanes for the treatment of brain cancers due to its ability to penetrate the central nervous system, which is often shielded from systemic administration of other anti-cancer drugs. Microtubule stabilization by TPI 287 may also have potential for the treatment of neurologic disorders affected by tau protein pathology. These include tauopathies such as Alzheimer’s disease and orphan diseases, such as progressive supranuclear palsy, corticobasal degeneration, and frontotemporal dementia.
About Glioblastoma
Glioblastoma (GBM) is the most aggressive and common form of brain cancer. Five-year survival after diagnosis is about 5%. The Central Brain Tumor Registry estimates that about 26,070 primary malignant brain tumors cases will be diagnosed in the US in 2017, 46% of which will be GBM. Typical front-line treatments include stereotactic or whole brain radiotherapy plus temozolomide (Temodar®). Patients with recurrent disease are candidates for treatment with Avastin®, the last drug approved by FDA for this disease.
About Cortice Biosciences
Cortice Biosciences, Inc. is a clinical-stage drug development company pioneering novel therapies for the treatment of oncologic and neurologic disease indications with urgent unmet medical need. More information can be found at www.corticebiosciences.com.
Contact: Cortice Biosciences, Inc. 646-747-9090 [email protected]
